CohBar and Morphogenesis Enter into Merger Agreement
Wednesday, May 24, 2023
CohBar Morphogenesis announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
The combined company will focus on advancing Morphogenesis’ two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. Combined company will operate under the name “TuHURA Biosciences” and advance a personalised cancer vaccine platform and preclinical tumour microenvironment modulators.
The proposed merger with CohBar, which comes at a pivotal time for Morphogenesis aims to initiate Phase 2/3 registration study for IFx-Hu2.0 early next year. The technology platforms have the potential to significantly increase the number of cancer patients that respond to immunotherapies, such as checkpoint inhibitors. This transaction serves as a significant next step in the advancement of important mission.
Combining with Morphogenesis and leveraging their late-stage pipeline of novel immuno-oncology technologies represents the best path forward for stockholders and has the potential to deliver near and long-term value.
